Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

Issa F. Khouri*, Ming S. Lee, Rima M. Saliba, Gu Jun, Luis Fayad, Anas Younes, Barbara Pro, Sandra Acholonu, Peter McLaughlin, Ruth L. Katz, Richard E. Champlin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

121 Scopus citations


Purpose: Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma. Patients and Methods: Eighteen patients were treated in one of two consecutive trials. Thirteen patients underwent a conditioning regimen of fludarabine (30 mg/m2 daily for 3 days), cyclophosphamide (750 mg/m2 daily for 3 days), and high-dose rituximab. For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg/m 2 daily for 4 days), fludarabine (30 mg/m2 daily for 2 days), and cytarabine (1,000 mg/m2 daily for 2 days). Tacrolimus and methotrexate were used for graft-versus-host disease prophylaxis. Results: The median age was 56.5 years. Patients underwent a median of three prior chemotherapy regimens. Prior autologous transplantation failed in five (28%) patients and 16 (89%) had chemosensitive disease. Donor cell engraftment occurred in all patients. Eight patients (44%) required no platelet or RBC transfusion, and acute graft-versus-host disease of greater than grade 2 did not develop in any patient. The day-100 mortality was 0%. Complete remission (CR) occurred in 17 patients. Three patients progressed, and one was reinduced into continuous CR with donor lymphocyte infusion. With a median follow-up period of 26 months, the actuarial probability of current-event-free-survival at 3 years was 82% (95% CI, 65% to 99%). Conclusion: Our data suggest that nonablative allogeneic transplantation is a safe and potentially effective strategy for patients with relapsed and chemosensitive mantle-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)4407-4412
Number of pages6
JournalJournal of Clinical Oncology
Issue number23
StatePublished - Dec 1 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma'. Together they form a unique fingerprint.

Cite this